Hatteras Venture Partners

Atsena Therapeutics is a clinical-stage gene therapy company dedicated to developing innovative treatments for inherited retinal diseases. The company focuses on therapies for conditions such as X-linked retinoschisis and GUCY2D-associated Leber congenital amaurosis. Utilizing an advanced adeno-associated virus (AAV) technology platform, including a novel spreading capsid, Atsena aims to target specific retinal conditions to prevent blindness resulting from genetic mutations. Their research is centered on providing effective ocular gene therapies that address significant challenges associated with inherited retinal diseases, with the goal of reversing or halting vision loss.

410 Medical is a healthcare technology company based in Durham, North Carolina, founded in 2013. The company has developed an innovative rapid infuser device designed to facilitate the swift delivery of fluids to critically ill patients in need of volume resuscitation. This device enhances the speed and efficiency of fluid administration, significantly improving care for patients suffering from life-threatening conditions such as sepsis and shock. By enabling a single healthcare provider to quickly set up and deliver vital fluids, the solution minimizes provider fatigue and allows for simultaneous attention to other patient care needs. It is particularly beneficial in pre-hospital settings and emergency departments, where rapid response is essential and resources may be limited.

BEKhealth is a clinical research software company that utilizes an AI-powered platform to enhance the efficiency of clinical trials and observational studies. By automating various processes, BEKhealth enables organizations to better understand their patient populations, optimize feasibility, and speed up site selection. The platform extracts and processes both structured and unstructured data from electronic medical records, allowing for a more comprehensive understanding of trial eligibility criteria. This capability leads to the identification of significantly more protocol-eligible candidates, resulting in a tenfold increase in qualified patients and halving the enrollment timeline. Through its innovative approach, BEKhealth aims to reduce costs and streamline the overall clinical research process for its clients.

Synaptrix specializes in developing innovative, non-opioid pain management solutions. The company focuses on creating medical devices that employ neuromodulation technology, using electrical or chemical stimulation to alleviate postoperative pain without compromising motor function or touch. This approach aims to provide healthcare professionals with effective, long-lasting alternatives to opioids, promoting rehabilitation and reducing the need for these medications.

HistoSonics, Inc. is a medical technology company based in Plymouth, Minnesota, established in 2009. It specializes in developing non-invasive tumor ablation systems, notably the Edison platform. This innovative technology employs sonic beam therapy to deliver pulsed sound energy into the body, effectively liquefying and destroying targeted tissues at the sub-cellular level. By harnessing advanced imaging and proprietary sensing technology, HistoSonics provides personalized treatments with high precision and control, allowing physicians to continuously monitor the treatment's effects in real time. The platform aims to offer a safer alternative to traditional interventional and surgical methods by minimizing undesirable side effects associated with these approaches.

Endogenex is a medical technology company founded in 2017, focused on developing innovative solutions for patients with type 2 diabetes. The company has created an endoscopic procedure that employs pulsed electric fields to regenerate the duodenal mucosa, aiming to enhance glycemic control in individuals suffering from this condition. By providing a novel therapy, Endogenex seeks to empower patients to better manage their blood glucose levels and improve their overall health outcomes.

AtaCor Medical, Inc. is a medical device company based in San Clemente, California, specializing in innovative solutions for cardiac pacing and rhythm management. Founded in 2014, the company has developed the AtaCor EV Temporary Pacing System, which allows for temporary pacing through a parasternal approach. This system advances a custom pacing lead into the extracardiac tissue between the ribs and pericardium, effectively restoring cardiac rhythm without the need for traditional pacing leads or hardware that typically attach directly to the heart. By facilitating quick deployment of temporary or emergency pacing therapy, AtaCor Medical addresses critical needs in cardiac care.

iVEAcare is a company focused on developing innovative neuromodulation therapies to address unmet clinical needs in chronic disease management. The firm specializes in next-generation technology that delivers targeted electrical stimulation to specific areas of the brain or spinal cord. By creating advanced devices and software, iVEAcare aims to enable medical professionals to devise therapies that are both more effective and less invasive than traditional treatment methods. This approach not only enhances treatment efficacy but also broadens access to therapies for a wider range of patients suffering from chronic conditions.

Veralox Therapeutics specializes in the development of small molecule therapeutics aimed at addressing the underlying pathologies of thrombosis and type one diabetes. The company focuses on innovative treatment paradigms informed by a deep understanding of the molecular mechanisms involved in these diseases. By targeting conditions such as heparin-induced thrombocytopenia and thrombosis, Veralox Therapeutics aims to enhance patient outcomes and facilitate complete recovery from diabetes. Through its research and development efforts, the company seeks to provide effective and transformative therapies for individuals affected by these serious health conditions.

410 Medical is a healthcare technology company based in Durham, North Carolina, founded in 2013. The company has developed an innovative rapid infuser device designed to facilitate the swift delivery of fluids to critically ill patients in need of volume resuscitation. This device enhances the speed and efficiency of fluid administration, significantly improving care for patients suffering from life-threatening conditions such as sepsis and shock. By enabling a single healthcare provider to quickly set up and deliver vital fluids, the solution minimizes provider fatigue and allows for simultaneous attention to other patient care needs. It is particularly beneficial in pre-hospital settings and emergency departments, where rapid response is essential and resources may be limited.

Myeloid Therapeutics is an immunology company dedicated to leveraging innovative technologies to harness the potential of myeloid cells for the treatment of cancer and other diseases. The company has developed the ATAK platform, which focuses on reprogramming innate immune cells to enhance their ability to target and eliminate cancerous cells. Initially, Myeloid Therapeutics is advancing a cell therapy program aimed at treating T cell lymphoma, as well as a primed monocyte strategy for glioblastoma. The versatility of the ATAK platform allows for scalability across various treatment modalities and disease areas, facilitating collaboration with partners to expand its applications in the field of immunotherapy.

Ten63 Therapeutics, Inc. is a biotechnology company based in Chapel Hill, North Carolina, focused on developing potent therapeutics for medically validated yet undruggable targets. Founded in 2017, the company utilizes its innovative platform, COPPER, which combines machine learning-based computational chemistry with advanced physical modeling to explore an extensive chemical space. This approach allows Ten63 Therapeutics to discover novel drug candidates for some of the most lethal diseases by employing proprietary algorithms for scaffold redesign and optimizing chemical design. By integrating these technologies, the company aims to produce durable therapies and improve drug resistance prediction, ultimately addressing challenges in drug development for previously intractable targets.

Aer Therapeutics is a biopharmaceutical company focused on developing innovative treatments for lung diseases characterized by excess mucus and mucus plugs, including chronic obstructive pulmonary disease (COPD), cystic fibrosis, and asthma. The company aims to address significant unmet needs in these respiratory conditions by advancing the treatment paradigm for mucus-mediated lung diseases.

Mercy BioAnalytics is a biotechnology company based in Natick, Massachusetts, founded in 2018 by Paul Blavin and Joseph Sedlak. The company focuses on improving cancer outcomes through early detection using a novel liquid biopsy assay platform. This platform analyzes tumor-derived extracellular vesicles, which are plentiful in blood and contain critical information about their parent cells. By leveraging these extracellular vesicles, Mercy BioAnalytics aims to enable the detection of various types of cancer at the earliest stages, thus improving the chances of successful treatment and patient survival.

Cardiosense is a company that focuses on developing a physiological waveform AI platform aimed at creating predictive biomarkers for disease detection and treatment. By mining raw biosignals, Cardiosense provides enhanced visibility into cardiac functions and employs advanced signal processing techniques to identify pre-symptomatic markers of cardiac disease. The company specializes in utilizing non-invasive sensors and proprietary algorithms, which allow healthcare professionals to monitor and analyze cardiac health signals effectively. This innovative approach enables the early detection of diseases, thereby facilitating improved patient care and health tracking.

410 Medical is a healthcare technology company based in Durham, North Carolina, founded in 2013. The company has developed an innovative rapid infuser device designed to facilitate the swift delivery of fluids to critically ill patients in need of volume resuscitation. This device enhances the speed and efficiency of fluid administration, significantly improving care for patients suffering from life-threatening conditions such as sepsis and shock. By enabling a single healthcare provider to quickly set up and deliver vital fluids, the solution minimizes provider fatigue and allows for simultaneous attention to other patient care needs. It is particularly beneficial in pre-hospital settings and emergency departments, where rapid response is essential and resources may be limited.

Boomerang Medical is a female-led bioelectronic medical technology company based in Mountain View, California, on the campus of El Camino Hospital. The firm is dedicated to revolutionizing the management of autoimmune diseases through the development of innovative bioelectric neuromodulation technologies. Boomerang Medical's commitment to advancing treatment options is underscored by its receipt of Breakthrough Device Designation from the FDA for its technology aimed at treating Crohn's disease and ulcerative colitis. By focusing on improving the quality of life for patients, Boomerang Medical seeks to disrupt traditional treatment paradigms in the field of autoimmune illnesses.

RapidPulse, Inc. is a privately held medical device company focused on creating minimally invasive vascular products specifically for the treatment of ischemic stroke. The company's flagship innovation is the RapidPulse™ Cyclic Aspiration System, which features an advanced aspiration pump designed to facilitate the rapid and consistent removal of blood clots from the brain. This technology aims to enhance patient outcomes in the neurovascular field. RapidPulse is a spinout from Syntheon LLC, a medical device incubator committed to developing groundbreaking products within the industry.

Code Biotherapeutics is a next-generation gene therapy company pioneering the development of targeted non-viral gene therapies to treat serious and life-threatening genetic diseases. Code Bio leverages its novel multivalent synthetic DNA delivery platform, 3DNA, which has been engineered to overcome many of the challenges inherent with viral-based gene therapies such as immunogenicity, size and delivery limitations, re-dosability, and manufacturing complexity. The company is advancing an internal pipeline focused on select rare disease programs as well as establishing partnerships to take forward programs in both rare and prevalent diseases.

Wildflower Health, Inc. is a health engagement platform based in San Francisco, California, that provides smartphone-based health programs aimed at connecting healthcare payers with families across the United States. Founded in 2012, the company offers a maternity program called Due Date Plus, which addresses engagement challenges by assisting women in early pregnancy and facilitating connections with care managers. Additionally, Wildflower Health provides GROW, a family health program that focuses on mothers and encompasses pediatric and family health. Its platform delivers personalized health milestones based on age and gender, along with resources such as on-device messaging, appointment reminders, health risk assessments, and provider referrals. By utilizing user-centered design and technology, Wildflower Health aims to empower families to make informed healthcare decisions and support their individual health needs over time.

Huma.AI, Inc. is a technology company based in Palo Alto, California, founded in 2016. It specializes in developing a knowledge automation platform aimed at improving efficiency within the healthcare and pharmaceutical industries. The platform addresses the challenges posed by complex and disparate data systems by connecting various data silos through natural human language. By extracting insights from unstructured data, such as documents and free text, Huma.AI enables users—including companies, scientists, and clinicians—to easily access information and make informed decisions quickly. This innovative approach not only streamlines data access but also allows users to interact with data using everyday language, thereby enhancing the decision-making process in healthcare.

AN2 Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Menlo Park, California, focused on the research, development, and commercialization of innovative medicines for infectious diseases. Founded in 2017, the company aims to address significant unmet medical needs through its development of novel therapeutics. Its lead product candidate, epetraborole, is a once-daily oral treatment designed for patients suffering from chronic non-tuberculous mycobacterial lung disease. AN2 Therapeutics is committed to leveraging advanced biomedical expertise to create transformative solutions for patients dealing with serious and rare infectious diseases. The company has also established a strategic partnership with Brii Biosciences to enhance its development efforts.

Tune Therapeutics is a biotechnology company focused on developing innovative cell and gene therapies. It employs an epigenetic programming platform to create novel therapeutic pathways, aiming to treat severe diseases without modifying the underlying DNA sequence.

Trefoil Therapeutics is a biotechnology company dedicated to developing innovative therapies for endothelial cell-mediated diseases, particularly those affecting the cornea. Utilizing its proprietary engineered fibroblast growth factor-1 technology platform, Trefoil aims to create first-in-class regenerative pharmacologic treatments for conditions such as Fuchs dystrophy and other serious corneal diseases that can lead to preventable blindness. The company is currently focused on a topical eye drop formulation known as TTHX1114, designed to treat ulcerative conditions on the cornea's surface, which can result in corneal scarring and significant vision loss. With a management team boasting over 100 years of combined experience in pharmaceutical development and commercialization, Trefoil strives to enhance human health through protein-engineered drug therapies. As an early-stage company, it has received recognition from the biopharmaceutical funding community for its innovative business approach.

GeneCentric Diagnostics is engaged in the development and commercialization of molecular diagnostic tests aimed at assisting oncologists and patients in cancer treatment. The company has established two primary platform technologies: The Lung Subtype Platform (LSP), which classifies lung cancer patients into specific subtypes to guide therapeutic choices, and the Hypoxia Signature, designed to identify patients likely to benefit from anti-angiogenesis therapies. The LSP has been licensed to Laboratory Corporation of America Holdings and is available as HistoPlusSM: Lung Cancer through its Integrated Oncology division. GeneCentric's innovative partnership model facilitates the translation of significant cancer research into diagnostics that are clinically adopted by pathologists and clinicians. Incorporated in 2011 and located in Durham, North Carolina, GeneCentric aims to enhance treatment outcomes by enabling more precise targeting of therapeutic compounds based on tumor biology.

GoCheck, formerly known as Gobiquity, Inc., is a technology company based in Aliso Viejo, California, that specializes in mobile health applications aimed at the early detection and prevention of eye diseases in children. The company's flagship product, GoCheck Kids, is a smartphone app designed for the screening of amblyopia risk factors, adhering to guidelines established by the American Association for Pediatric Ophthalmology and Strabismus. With a focus on affordability, GoCheck Kids reduces the cost of vision screening by over 60% by utilizing the manufacturing capabilities of smartphones. The app is FDA-registered and CE certified, and it is currently utilized by over 6,500 pediatric teams across the U.S. and Europe. By facilitating early detection, GoCheck aims to combat vision impairment, a leading disabling condition among children, which can severely impact learning and overall health outcomes.

Elligo Health Research, Inc. is a healthcare organization focused on improving the clinical research landscape by bringing research directly to healthcare clinics. Founded in 2016 and headquartered in Austin, Texas, the company utilizes advanced healthcare informatics and electronic health records to enhance patient and physician participation in clinical trials. By enabling physicians to conduct trials within their practices, Elligo eliminates common barriers related to patient enrollment and study delays, while providing essential infrastructure and support. This approach not only accelerates the development of new pharmaceutical, biotechnology, and medical device products but also ensures that patients benefit from access to cutting-edge therapies without the logistical challenges of traditional trials. Elligo's model empowers physicians and offers patients the opportunity to contribute to clinical research, ultimately fostering advancements in healthcare for future generations.

Qvella Corporation is a Toronto-based molecular diagnostics company founded in 2009 by a group of scientists and engineers. The company focuses on transforming clinical microbiology by significantly reducing the time required to obtain results for bloodstream infections. Qvella's innovative Field Activated Sample Treatment (FAST™) technology employs a novel electrical lysing technique, known as e-lysis™, which facilitates the rapid and fully automated detection of infectious agents directly from unenriched biological samples. This capability allows clinicians to identify microorganisms in infected whole blood samples without the lengthy sample processing typically required, ultimately enhancing patient outcomes and saving lives.

Vigil Neuroscience Inc is a therapeutics company focused on developing treatments for both rare and common neurodegenerative diseases by targeting microglia, the brain's immune cells. The company aims to restore the vigilance of these cells to improve patient outcomes. Vigil is advancing its lead candidate, a monoclonal antibody TREM2 agonist, through Phase 1 clinical studies, while also working on VG-3927, an orally available small molecule TREM2 agonist. These efforts are part of a broader strategy to build a robust pipeline of therapies supported by the understanding of microglia biology as a critical therapeutic pathway. Vigil's clinical candidate, iluzanebart, is currently undergoing a Phase 2 proof-of-concept trial in patients with ALSP, marking a significant step in the company's commitment to precision-based neuroscience drug development.

RapidPulse, Inc. is a privately held medical device company focused on creating minimally invasive vascular products specifically for the treatment of ischemic stroke. The company's flagship innovation is the RapidPulse™ Cyclic Aspiration System, which features an advanced aspiration pump designed to facilitate the rapid and consistent removal of blood clots from the brain. This technology aims to enhance patient outcomes in the neurovascular field. RapidPulse is a spinout from Syntheon LLC, a medical device incubator committed to developing groundbreaking products within the industry.

Veralox Therapeutics specializes in the development of small molecule therapeutics aimed at addressing the underlying pathologies of thrombosis and type one diabetes. The company focuses on innovative treatment paradigms informed by a deep understanding of the molecular mechanisms involved in these diseases. By targeting conditions such as heparin-induced thrombocytopenia and thrombosis, Veralox Therapeutics aims to enhance patient outcomes and facilitate complete recovery from diabetes. Through its research and development efforts, the company seeks to provide effective and transformative therapies for individuals affected by these serious health conditions.

Standard Bariatrics is a medical device company based in Cincinnati, Ohio, specializing in the development of surgical instruments for weight-loss surgeries, particularly laparoscopic sleeve gastrectomy. Founded in 2014, the company has created a series of disposable surgical tools designed to work alongside general-use endoscopic staplers. These innovative tools help surgeons standardize their techniques, reduce variability, and minimize waste during procedures. By decreasing the number of cartridges needed for each surgery, Standard Bariatrics enables healthcare providers to lower costs while ensuring consistent surgical outcomes.

Boston Immune Technologies & Therapeutics, Inc. is a biopharmaceutical company focused on developing immune-based therapies for cancer and infectious diseases. Incorporated in 2011 and located in Winchester, Massachusetts, the company has created a platform that targets the tumor necrosis factor receptor 2 (TNFR2) oncogene and the specific population of TNFR2 regulatory T cells within the tumor microenvironment. This innovative approach aims to enhance immunotherapy strategies, particularly for chronic infectious diseases, by leveraging the body's immune system to combat various health challenges.

StrideBio, Inc. is a gene therapy company based in Durham, North Carolina, focused on developing innovative genetic medicines for rare diseases. Founded in 2015, the company utilizes a proprietary structure-inspired adeno-associated virus (AAV) vector engineering platform to create unique and differentiated vectors. These vectors are designed to improve upon naturally occurring AAV serotypes, addressing limitations of first-generation gene therapies. StrideBio's technologies facilitate gene addition, silencing, and editing, providing potential curative options for patients with severe medical conditions. By combining structural insights with accelerated evolution, StrideBio aims to produce novel AAV capsids capable of evading neutralizing antibodies, ultimately enhancing treatment outcomes for those affected by rare diseases.

Artizan Biosciences, Inc. is a biotechnology company focused on developing small molecule drugs for human use, particularly targeting diseases linked to intestinal inflammation. Founded in 2016 and headquartered in New Haven, Connecticut, the company employs its proprietary IgA-SEQ technology platform to identify and characterize disease-driving bacteria within the intestinal microbiota. This innovative approach aims to create precision therapeutics that address the root causes of various serious conditions, including digestive disorders, obesity, autoimmune diseases, and a range of other health issues affecting the skin, lungs, and central nervous system. By focusing on unmet medical needs, Artizan Biosciences seeks to provide novel treatment options for patients.

Myeloid Therapeutics is an immunology company dedicated to leveraging innovative technologies to harness the potential of myeloid cells for the treatment of cancer and other diseases. The company has developed the ATAK platform, which focuses on reprogramming innate immune cells to enhance their ability to target and eliminate cancerous cells. Initially, Myeloid Therapeutics is advancing a cell therapy program aimed at treating T cell lymphoma, as well as a primed monocyte strategy for glioblastoma. The versatility of the ATAK platform allows for scalability across various treatment modalities and disease areas, facilitating collaboration with partners to expand its applications in the field of immunotherapy.

NoviSci is a software analytics and services company focused on enhancing population health outcomes, particularly for vulnerable patients with complex health conditions. The company leverages advanced data science techniques to visualize and analyze health data, employing modern epidemiological methods grounded in sound scientific principles. Through its innovative tools, NoviSci aims to improve the health and well-being of individuals by providing insights that drive better decision-making in healthcare settings.

Atsena Therapeutics is a clinical-stage gene therapy company dedicated to developing innovative treatments for inherited retinal diseases. The company focuses on therapies for conditions such as X-linked retinoschisis and GUCY2D-associated Leber congenital amaurosis. Utilizing an advanced adeno-associated virus (AAV) technology platform, including a novel spreading capsid, Atsena aims to target specific retinal conditions to prevent blindness resulting from genetic mutations. Their research is centered on providing effective ocular gene therapies that address significant challenges associated with inherited retinal diseases, with the goal of reversing or halting vision loss.

Vigil Neuroscience Inc is a therapeutics company focused on developing treatments for both rare and common neurodegenerative diseases by targeting microglia, the brain's immune cells. The company aims to restore the vigilance of these cells to improve patient outcomes. Vigil is advancing its lead candidate, a monoclonal antibody TREM2 agonist, through Phase 1 clinical studies, while also working on VG-3927, an orally available small molecule TREM2 agonist. These efforts are part of a broader strategy to build a robust pipeline of therapies supported by the understanding of microglia biology as a critical therapeutic pathway. Vigil's clinical candidate, iluzanebart, is currently undergoing a Phase 2 proof-of-concept trial in patients with ALSP, marking a significant step in the company's commitment to precision-based neuroscience drug development.

Qvella Corporation is a Toronto-based molecular diagnostics company founded in 2009 by a group of scientists and engineers. The company focuses on transforming clinical microbiology by significantly reducing the time required to obtain results for bloodstream infections. Qvella's innovative Field Activated Sample Treatment (FAST™) technology employs a novel electrical lysing technique, known as e-lysis™, which facilitates the rapid and fully automated detection of infectious agents directly from unenriched biological samples. This capability allows clinicians to identify microorganisms in infected whole blood samples without the lengthy sample processing typically required, ultimately enhancing patient outcomes and saving lives.

Altis Biosystems, LLC is a biotechnology company specializing in the development of innovative stem cell technologies aimed at enhancing research in human biology. Established in 2015 and based in Chapel Hill, North Carolina, the company has created a patent-pending system known as RepliGut, which effectively recreates the human intestinal epithelium and colonic epithelium. This advanced technology enables the generation of a layer of human or animal intestinal stem and differentiated cells from both the small and large intestines. Altis Biosystems' products are primarily utilized in preclinical studies for disease modeling, precision medicine, microbiome research, and compound screening, serving the needs of pharmaceutical and biotechnology companies. By utilizing normal human intestinal tissue, the company aims to improve drug development processes while minimizing reliance on animal testing.

CVRx, Inc. is a medical device company headquartered in Minneapolis, Minnesota, that specializes in the development of implantable technologies for the treatment of high blood pressure and heart failure. Founded in 2000, the company has created Barostim NEO, a neuro-modulation therapy that activates the body's natural mechanisms to regulate blood pressure and address heart failure progression. This therapy utilizes an implantable system that is tailored to the individual needs of patients. CVRx also offers the Rheos platform, which includes an implantable pulse generator and carotid sinus leads designed to deliver therapeutic energy to the carotid arteries. With a focus on minimally invasive solutions, CVRx primarily serves patients and healthcare professionals in the United States and internationally, including markets in the United Kingdom, the Netherlands, Italy, and Germany.

Shattuck Labs, Inc. is a clinical-stage biotechnology company based in Austin, Texas, focused on developing innovative therapeutics for cancer and autoimmune diseases. Founded in 2016, the company is advancing its proprietary Agonist Redirected Checkpoint (ARC) platform, which utilizes dual-function fusion proteins to enhance immune responses against tumors. Its lead product candidate, SL-172154, is currently undergoing Phase 1 clinical trials for ovarian cancer, aiming to inhibit the CD47/SIRPa checkpoint interaction while activating the CD40 receptor to restore and amplify anti-tumor immune responses. Additionally, Shattuck Labs is collaborating with Takeda Pharmaceuticals on SL-279252, which targets the PD-1/PD-L1 interaction and activates the OX40 receptor, and is also in Phase 1 trials for patients with advanced solid tumors and lymphoma. Through its innovative approach to immuno-oncology, Shattuck Labs seeks to address various cancer types and improve treatment options for patients.

AtaCor Medical, Inc. is a medical device company based in San Clemente, California, specializing in innovative solutions for cardiac pacing and rhythm management. Founded in 2014, the company has developed the AtaCor EV Temporary Pacing System, which allows for temporary pacing through a parasternal approach. This system advances a custom pacing lead into the extracardiac tissue between the ribs and pericardium, effectively restoring cardiac rhythm without the need for traditional pacing leads or hardware that typically attach directly to the heart. By facilitating quick deployment of temporary or emergency pacing therapy, AtaCor Medical addresses critical needs in cardiac care.

Atsena Therapeutics is a clinical-stage gene therapy company dedicated to developing innovative treatments for inherited retinal diseases. The company focuses on therapies for conditions such as X-linked retinoschisis and GUCY2D-associated Leber congenital amaurosis. Utilizing an advanced adeno-associated virus (AAV) technology platform, including a novel spreading capsid, Atsena aims to target specific retinal conditions to prevent blindness resulting from genetic mutations. Their research is centered on providing effective ocular gene therapies that address significant challenges associated with inherited retinal diseases, with the goal of reversing or halting vision loss.

410 Medical is a healthcare technology company based in Durham, North Carolina, founded in 2013. The company has developed an innovative rapid infuser device designed to facilitate the swift delivery of fluids to critically ill patients in need of volume resuscitation. This device enhances the speed and efficiency of fluid administration, significantly improving care for patients suffering from life-threatening conditions such as sepsis and shock. By enabling a single healthcare provider to quickly set up and deliver vital fluids, the solution minimizes provider fatigue and allows for simultaneous attention to other patient care needs. It is particularly beneficial in pre-hospital settings and emergency departments, where rapid response is essential and resources may be limited.

Graybug Vision, Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative treatments for diseases affecting the retina and optic nerve. Founded in 2011 and based in Redwood City, California, the company focuses on chronic vision-threatening conditions. Its lead product candidate, GB-102, is an intravitreal injection undergoing clinical trials for wet age-related macular degeneration and diabetic macular edema. Additionally, Graybug is advancing GB-103, a once-a-year formulation aimed at treating diabetic retinopathy, and GB-401, a depot formulation targeting primary open-angle glaucoma. The company utilizes proprietary micro- and nanoparticle controlled release technologies to enhance drug delivery in ocular tissues, thereby improving patient compliance and clinical outcomes. Graybug Vision was previously known as Graybug LLC before its rebranding in 2016.

Trefoil Therapeutics is a biotechnology company dedicated to developing innovative therapies for endothelial cell-mediated diseases, particularly those affecting the cornea. Utilizing its proprietary engineered fibroblast growth factor-1 technology platform, Trefoil aims to create first-in-class regenerative pharmacologic treatments for conditions such as Fuchs dystrophy and other serious corneal diseases that can lead to preventable blindness. The company is currently focused on a topical eye drop formulation known as TTHX1114, designed to treat ulcerative conditions on the cornea's surface, which can result in corneal scarring and significant vision loss. With a management team boasting over 100 years of combined experience in pharmaceutical development and commercialization, Trefoil strives to enhance human health through protein-engineered drug therapies. As an early-stage company, it has received recognition from the biopharmaceutical funding community for its innovative business approach.

Artizan Biosciences, Inc. is a biotechnology company focused on developing small molecule drugs for human use, particularly targeting diseases linked to intestinal inflammation. Founded in 2016 and headquartered in New Haven, Connecticut, the company employs its proprietary IgA-SEQ technology platform to identify and characterize disease-driving bacteria within the intestinal microbiota. This innovative approach aims to create precision therapeutics that address the root causes of various serious conditions, including digestive disorders, obesity, autoimmune diseases, and a range of other health issues affecting the skin, lungs, and central nervous system. By focusing on unmet medical needs, Artizan Biosciences seeks to provide novel treatment options for patients.

Elligo Health Research, Inc. is a healthcare organization focused on improving the clinical research landscape by bringing research directly to healthcare clinics. Founded in 2016 and headquartered in Austin, Texas, the company utilizes advanced healthcare informatics and electronic health records to enhance patient and physician participation in clinical trials. By enabling physicians to conduct trials within their practices, Elligo eliminates common barriers related to patient enrollment and study delays, while providing essential infrastructure and support. This approach not only accelerates the development of new pharmaceutical, biotechnology, and medical device products but also ensures that patients benefit from access to cutting-edge therapies without the logistical challenges of traditional trials. Elligo's model empowers physicians and offers patients the opportunity to contribute to clinical research, ultimately fostering advancements in healthcare for future generations.

Qvella Corporation is a Toronto-based molecular diagnostics company founded in 2009 by a group of scientists and engineers. The company focuses on transforming clinical microbiology by significantly reducing the time required to obtain results for bloodstream infections. Qvella's innovative Field Activated Sample Treatment (FAST™) technology employs a novel electrical lysing technique, known as e-lysis™, which facilitates the rapid and fully automated detection of infectious agents directly from unenriched biological samples. This capability allows clinicians to identify microorganisms in infected whole blood samples without the lengthy sample processing typically required, ultimately enhancing patient outcomes and saving lives.

WalletFi is a subscription management solution tailored for financial institutions and fintech companies. It develops a white-label application that helps users manage their recurring charges effectively. Utilizing machine learning technology, WalletFi's application identifies subscriptions, recurring payments, and Card-on-File merchants. This capability provides users with personalized insights and detailed analytics, allowing financial institutions to enhance customer engagement and wellness. By offering measurable returns on investment, WalletFi empowers its clients to expand their influence within the customer base.

Kymera Therapeutics, Inc. is a biopharmaceutical company based in Watertown, Massachusetts, specializing in targeted protein degradation. Founded in 2015, the company employs a proprietary platform that utilizes the body's natural protein degradation system to selectively degrade disease-causing proteins. Kymera is advancing several therapeutic programs, including its IRAK4 program aimed at treating immunology-inflammation diseases such as hidradenitis suppurativa, atopic dermatitis, and rheumatoid arthritis. Additionally, it is developing the IRAKIMiD program for MYD88-mutated diffuse large B cell lymphoma and the STAT3 program targeting hematologic malignancies, solid tumors, and autoimmune diseases. By focusing on previously untreatable conditions and using innovative small molecule modalities, Kymera Therapeutics aims to revolutionize drug discovery and create effective treatments for challenging diseases.

Ribometrix, Inc. is a biotechnology company founded in 2014 and headquartered in Durham, North Carolina. The company specializes in discovering and developing small molecule drugs that target functional three-dimensional RNA structures, aiming to address various human diseases. Ribometrix employs advanced techniques in RNA structural analysis, utilizing proprietary methods and state-of-the-art tools, including artificial intelligence and machine learning, to identify novel small molecules that can inhibit the production of disease-associated proteins. By focusing on RNA biology, Ribometrix seeks to lead a new paradigm in small molecule therapeutics, enhancing the understanding and modulation of RNA's role in disease mechanisms.

Qpex Biopharma is a San Diego-based biopharmaceutical company founded in 2018, focused on developing innovative therapies to address the growing challenge of antimicrobial resistance. The company specializes in creating a pipeline of antibiotic drugs aimed at treating infectious diseases in both inpatient and outpatient settings. With a strong emphasis on the discovery, development, and regulatory approval of anti-infective medicines, Qpex Biopharma leverages its expertise and experience in collaboration with public and private partnerships to meet critical medical needs. The company's mission is to provide effective solutions for healthcare professionals facing the complexities of resistant infections, thereby enhancing treatment options for patients.

PhaseBio Pharmaceuticals, Inc., established in 2002 and based in Malvern, Pennsylvania, is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for cardiopulmonary diseases. Its primary focus is on PB2452, a reversal agent for the antiplatelet drug ticagrelor, currently in Phase III trials for managing uncontrolled bleeding events or urgent surgeries. Additionally, PhaseBio is developing PB1046, a fusion protein in Phase IIb trials for treating pulmonary arterial hypertension, and PB6440, an oral agent for resistant hypertension. The company's proprietary technology, elastin-like polypeptides (ELPs), enhances the stability, bioavailability, and efficacy of proteins and peptides, aiming to improve patient outcomes and reduce side effects.

ORIG3N, Inc. is a biotechnology company focused on developing innovative treatments for rare genetically inherited diseases, particularly targeting conditions related to the heart, liver, and neurodegeneration. Founded in 2014 and based in Boston, Massachusetts, ORIG3N utilizes induced pluripotent stem cell technology that allows for the differentiation of cells into any type found in the body. This technology is employed to test drug efficacy, screen for medication toxicity, and create personalized treatment pathways. The company offers a range of products, including LifeProfiles, which provides genetic insights related to fitness, metabolism, and exercise recovery; the Run DNA test for optimizing running performance; AURA, which assesses skin health; and Life Capsule, a repository for blood cells aimed at regenerative medicine development.

StrideBio, Inc. is a gene therapy company based in Durham, North Carolina, focused on developing innovative genetic medicines for rare diseases. Founded in 2015, the company utilizes a proprietary structure-inspired adeno-associated virus (AAV) vector engineering platform to create unique and differentiated vectors. These vectors are designed to improve upon naturally occurring AAV serotypes, addressing limitations of first-generation gene therapies. StrideBio's technologies facilitate gene addition, silencing, and editing, providing potential curative options for patients with severe medical conditions. By combining structural insights with accelerated evolution, StrideBio aims to produce novel AAV capsids capable of evading neutralizing antibodies, ultimately enhancing treatment outcomes for those affected by rare diseases.

Standard Bariatrics is a medical device company based in Cincinnati, Ohio, specializing in the development of surgical instruments for weight-loss surgeries, particularly laparoscopic sleeve gastrectomy. Founded in 2014, the company has created a series of disposable surgical tools designed to work alongside general-use endoscopic staplers. These innovative tools help surgeons standardize their techniques, reduce variability, and minimize waste during procedures. By decreasing the number of cartridges needed for each surgery, Standard Bariatrics enables healthcare providers to lower costs while ensuring consistent surgical outcomes.

Clinipace Inc. is a clinical research organization based in Morrisville, North Carolina, with additional offices in Boulder, Colorado, Buenos Aires, Argentina, São Paulo, Brazil, and various locations in Europe and Asia Pacific. Founded in 2003, the company provides fully integrated clinical research services tailored for venture-backed, mid-tier, and strategic pharmaceutical, biotechnology, and medical device companies both in the United States and internationally. Clinipace specializes in a range of therapeutic areas, including oncology, nephrology, gastroenterology, cardiology, and immunology, among others. Its comprehensive suite of services encompasses project management, clinical monitoring, biostatistics, patient recruitment, regulatory affairs, and legal representation, allowing for a collaborative and flexible approach to clinical research that distinguishes it from traditional contract research organizations.

Elligo Health Research, Inc. is a healthcare organization focused on improving the clinical research landscape by bringing research directly to healthcare clinics. Founded in 2016 and headquartered in Austin, Texas, the company utilizes advanced healthcare informatics and electronic health records to enhance patient and physician participation in clinical trials. By enabling physicians to conduct trials within their practices, Elligo eliminates common barriers related to patient enrollment and study delays, while providing essential infrastructure and support. This approach not only accelerates the development of new pharmaceutical, biotechnology, and medical device products but also ensures that patients benefit from access to cutting-edge therapies without the logistical challenges of traditional trials. Elligo's model empowers physicians and offers patients the opportunity to contribute to clinical research, ultimately fostering advancements in healthcare for future generations.

Wildflower Health, Inc. is a health engagement platform based in San Francisco, California, that provides smartphone-based health programs aimed at connecting healthcare payers with families across the United States. Founded in 2012, the company offers a maternity program called Due Date Plus, which addresses engagement challenges by assisting women in early pregnancy and facilitating connections with care managers. Additionally, Wildflower Health provides GROW, a family health program that focuses on mothers and encompasses pediatric and family health. Its platform delivers personalized health milestones based on age and gender, along with resources such as on-device messaging, appointment reminders, health risk assessments, and provider referrals. By utilizing user-centered design and technology, Wildflower Health aims to empower families to make informed healthcare decisions and support their individual health needs over time.

NurseGrid is a technology company founded by nurses and entrepreneurs, specializing in streamlining staffing and communication processes within healthcare facilities. They offer two primary products: NurseGrid Mobile and NurseGrid Manager. NurseGrid Mobile empowers over 300,000 registered nurses to manage complex schedules, connect with colleagues, and improve work-life balance via a highly-rated iOS app. Meanwhile, NurseGrid Manager assists nursing departments in simplifying team communication, staffing, and schedule management, complementing core scheduling systems like Kronos and McKesson. This enhances productivity, increases job satisfaction, and aids in nurse retention for healthcare facilities nationwide.

Qvella Corporation is a Toronto-based molecular diagnostics company founded in 2009 by a group of scientists and engineers. The company focuses on transforming clinical microbiology by significantly reducing the time required to obtain results for bloodstream infections. Qvella's innovative Field Activated Sample Treatment (FAST™) technology employs a novel electrical lysing technique, known as e-lysis™, which facilitates the rapid and fully automated detection of infectious agents directly from unenriched biological samples. This capability allows clinicians to identify microorganisms in infected whole blood samples without the lengthy sample processing typically required, ultimately enhancing patient outcomes and saving lives.

Ribometrix, Inc. is a biotechnology company founded in 2014 and headquartered in Durham, North Carolina. The company specializes in discovering and developing small molecule drugs that target functional three-dimensional RNA structures, aiming to address various human diseases. Ribometrix employs advanced techniques in RNA structural analysis, utilizing proprietary methods and state-of-the-art tools, including artificial intelligence and machine learning, to identify novel small molecules that can inhibit the production of disease-associated proteins. By focusing on RNA biology, Ribometrix seeks to lead a new paradigm in small molecule therapeutics, enhancing the understanding and modulation of RNA's role in disease mechanisms.

Rodin Therapeutics Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing therapeutics for cognitive disorders through epigenetic modulation. Founded in 2013, the company leverages insights into key epigenetic regulators of central nervous system (CNS) function to create innovative treatments. Rodin's approach involves harnessing the power of epigenetic regulation, particularly through the modulation of HDAC complexes, to restore synaptic function and enhance neuronal health in patients suffering from degenerative brain diseases. The company is supported by a team experienced in CNS drug development and has access to advanced structural biology capabilities. Rodin Therapeutics operates as a subsidiary of Alkermes Inc.

ORIG3N, Inc. is a biotechnology company focused on developing innovative treatments for rare genetically inherited diseases, particularly targeting conditions related to the heart, liver, and neurodegeneration. Founded in 2014 and based in Boston, Massachusetts, ORIG3N utilizes induced pluripotent stem cell technology that allows for the differentiation of cells into any type found in the body. This technology is employed to test drug efficacy, screen for medication toxicity, and create personalized treatment pathways. The company offers a range of products, including LifeProfiles, which provides genetic insights related to fitness, metabolism, and exercise recovery; the Run DNA test for optimizing running performance; AURA, which assesses skin health; and Life Capsule, a repository for blood cells aimed at regenerative medicine development.

StrideBio, Inc. is a gene therapy company based in Durham, North Carolina, focused on developing innovative genetic medicines for rare diseases. Founded in 2015, the company utilizes a proprietary structure-inspired adeno-associated virus (AAV) vector engineering platform to create unique and differentiated vectors. These vectors are designed to improve upon naturally occurring AAV serotypes, addressing limitations of first-generation gene therapies. StrideBio's technologies facilitate gene addition, silencing, and editing, providing potential curative options for patients with severe medical conditions. By combining structural insights with accelerated evolution, StrideBio aims to produce novel AAV capsids capable of evading neutralizing antibodies, ultimately enhancing treatment outcomes for those affected by rare diseases.

MATI Energy, founded in 2012 and headquartered in Durham, North Carolina, specializes in organic caffeinated energy drinks designed for health-conscious consumers seeking enhanced performance. The company offers a range of no-spike, no-crash beverages that provide a refreshing alternative to traditional energy drinks. These carbonated mixtures focus on delivering a natural boost without compromising on taste or using unhealthy ingredients, catering to individuals who prioritize both vitality and well-being in their daily routines.

NeuroTronik, spun out of medical technology incubator Synecor, is developing a medical device that could take the place of drugs currently used to heart failure. Read more about the company's technology,

Bivarus, Inc. is a Durham, North Carolina-based company that specializes in developing a cloud-based analytics platform aimed at enhancing the patient experience in healthcare settings. Founded in 2010, Bivarus emerged from academic research that established patient experience as a key factor in determining health outcomes. The platform provides healthcare leaders with real-time, actionable insights into factors affecting patient experience, provider performance, and overall service operations. By utilizing a sophisticated sampling algorithm, Bivarus delivers targeted measures to patients, enabling organizations to identify root causes of service issues and track quality improvement initiatives effectively. Additionally, Bivarus is recognized as a CMS-approved CAHPS® partner, offering comprehensive services that include measuring employee perceptions of organizational effectiveness and engagement. As a subsidiary of Press Ganey Holdings, Inc., Bivarus continues to play a pivotal role in transforming how healthcare organizations understand and enhance the patient experience.

HistoSonics, Inc. is a medical technology company based in Plymouth, Minnesota, established in 2009. It specializes in developing non-invasive tumor ablation systems, notably the Edison platform. This innovative technology employs sonic beam therapy to deliver pulsed sound energy into the body, effectively liquefying and destroying targeted tissues at the sub-cellular level. By harnessing advanced imaging and proprietary sensing technology, HistoSonics provides personalized treatments with high precision and control, allowing physicians to continuously monitor the treatment's effects in real time. The platform aims to offer a safer alternative to traditional interventional and surgical methods by minimizing undesirable side effects associated with these approaches.

Boragen Inc. is a biotechnology company based in Durham, North Carolina, founded in 2015. It specializes in the design and development of multifunctional small molecule boron solutions for applications in crop protection, animal health, and human health. Boragen's innovative synthetic chemistry platform enables the production of next-generation fungicides, including BAG8, a multisite fungicide, and BN2266, which targets mRNA processing. The company is also developing a dual function nematicide-fungicide for root protection and endo-parasiticides that can overcome resistance. By leveraging the unique properties of boron, Boragen aims to create sustainable agricultural solutions that reduce the probability of fungicide resistance and minimize chemical usage while maintaining efficacy across various sectors.

Artizan Biosciences, Inc. is a biotechnology company focused on developing small molecule drugs for human use, particularly targeting diseases linked to intestinal inflammation. Founded in 2016 and headquartered in New Haven, Connecticut, the company employs its proprietary IgA-SEQ technology platform to identify and characterize disease-driving bacteria within the intestinal microbiota. This innovative approach aims to create precision therapeutics that address the root causes of various serious conditions, including digestive disorders, obesity, autoimmune diseases, and a range of other health issues affecting the skin, lungs, and central nervous system. By focusing on unmet medical needs, Artizan Biosciences seeks to provide novel treatment options for patients.

Trefoil Therapeutics is a biotechnology company dedicated to developing innovative therapies for endothelial cell-mediated diseases, particularly those affecting the cornea. Utilizing its proprietary engineered fibroblast growth factor-1 technology platform, Trefoil aims to create first-in-class regenerative pharmacologic treatments for conditions such as Fuchs dystrophy and other serious corneal diseases that can lead to preventable blindness. The company is currently focused on a topical eye drop formulation known as TTHX1114, designed to treat ulcerative conditions on the cornea's surface, which can result in corneal scarring and significant vision loss. With a management team boasting over 100 years of combined experience in pharmaceutical development and commercialization, Trefoil strives to enhance human health through protein-engineered drug therapies. As an early-stage company, it has received recognition from the biopharmaceutical funding community for its innovative business approach.

G1 Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Research Triangle Park, North Carolina, focused on the discovery, development, and commercialization of small molecule therapeutics for cancer treatment. The company is advancing several key drug candidates, including trilaciclib, an intravenous cyclin-dependent kinases (CDK) 4/6 inhibitor currently in Phase 1b/2 clinical trials for extensive-stage small cell lung cancer and Phase 2 trials for first-line small cell lung cancer and metastatic triple-negative breast cancer. Additionally, G1 is developing lerociclib, an oral CDK4/6 inhibitor in Phase 1b/2a trials for breast cancer and Phase 1b trials for non-small cell lung cancer, as well as rintodestrant, an oral selective estrogen receptor degrader in Phase I/2 trials. The company collaborates with Quantum Leap Healthcare Collaborative to explore trilaciclib's potential in neoadjuvant treatment for locally advanced breast cancer. Founded in 2008, G1 Therapeutics aims to address unmet medical needs in oncology by enhancing the effectiveness of existing cancer therapies.

Graybug Vision, Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative treatments for diseases affecting the retina and optic nerve. Founded in 2011 and based in Redwood City, California, the company focuses on chronic vision-threatening conditions. Its lead product candidate, GB-102, is an intravitreal injection undergoing clinical trials for wet age-related macular degeneration and diabetic macular edema. Additionally, Graybug is advancing GB-103, a once-a-year formulation aimed at treating diabetic retinopathy, and GB-401, a depot formulation targeting primary open-angle glaucoma. The company utilizes proprietary micro- and nanoparticle controlled release technologies to enhance drug delivery in ocular tissues, thereby improving patient compliance and clinical outcomes. Graybug Vision was previously known as Graybug LLC before its rebranding in 2016.

Bivarus, Inc. is a Durham, North Carolina-based company that specializes in developing a cloud-based analytics platform aimed at enhancing the patient experience in healthcare settings. Founded in 2010, Bivarus emerged from academic research that established patient experience as a key factor in determining health outcomes. The platform provides healthcare leaders with real-time, actionable insights into factors affecting patient experience, provider performance, and overall service operations. By utilizing a sophisticated sampling algorithm, Bivarus delivers targeted measures to patients, enabling organizations to identify root causes of service issues and track quality improvement initiatives effectively. Additionally, Bivarus is recognized as a CMS-approved CAHPS® partner, offering comprehensive services that include measuring employee perceptions of organizational effectiveness and engagement. As a subsidiary of Press Ganey Holdings, Inc., Bivarus continues to play a pivotal role in transforming how healthcare organizations understand and enhance the patient experience.

ORIG3N, Inc. is a biotechnology company focused on developing innovative treatments for rare genetically inherited diseases, particularly targeting conditions related to the heart, liver, and neurodegeneration. Founded in 2014 and based in Boston, Massachusetts, ORIG3N utilizes induced pluripotent stem cell technology that allows for the differentiation of cells into any type found in the body. This technology is employed to test drug efficacy, screen for medication toxicity, and create personalized treatment pathways. The company offers a range of products, including LifeProfiles, which provides genetic insights related to fitness, metabolism, and exercise recovery; the Run DNA test for optimizing running performance; AURA, which assesses skin health; and Life Capsule, a repository for blood cells aimed at regenerative medicine development.

Qvella Corporation is a Toronto-based molecular diagnostics company founded in 2009 by a group of scientists and engineers. The company focuses on transforming clinical microbiology by significantly reducing the time required to obtain results for bloodstream infections. Qvella's innovative Field Activated Sample Treatment (FAST™) technology employs a novel electrical lysing technique, known as e-lysis™, which facilitates the rapid and fully automated detection of infectious agents directly from unenriched biological samples. This capability allows clinicians to identify microorganisms in infected whole blood samples without the lengthy sample processing typically required, ultimately enhancing patient outcomes and saving lives.

Medfusion, Inc. is a healthcare technology company based in Cary, North Carolina, specializing in patient engagement solutions that enhance communication between healthcare providers and patients. Founded in 1996, Medfusion offers a comprehensive patient engagement portal that encompasses clinical, administrative, and financial services. Its solutions include billing options such as online payments and payment plans, clinical tools for secure messaging and prescription requests, and front desk functionalities like appointment scheduling and patient registration. The company also provides mobile applications to facilitate patient access to health data and payment processing. Additionally, Medfusion's Practice Intelligence service assists healthcare practices in managing patient communication traffic effectively. By focusing on improving the patient experience and operational efficiency, Medfusion aims to support healthcare providers in delivering better services while also generating revenue.

Wildflower Health, Inc. is a health engagement platform based in San Francisco, California, that provides smartphone-based health programs aimed at connecting healthcare payers with families across the United States. Founded in 2012, the company offers a maternity program called Due Date Plus, which addresses engagement challenges by assisting women in early pregnancy and facilitating connections with care managers. Additionally, Wildflower Health provides GROW, a family health program that focuses on mothers and encompasses pediatric and family health. Its platform delivers personalized health milestones based on age and gender, along with resources such as on-device messaging, appointment reminders, health risk assessments, and provider referrals. By utilizing user-centered design and technology, Wildflower Health aims to empower families to make informed healthcare decisions and support their individual health needs over time.

NuSirt Sciences, Inc. is a biotechnology company based in Nashville, Tennessee, that focuses on developing innovative products for metabolic diseases linked to over-nutrition, such as obesity and diabetes. Established in 2007, the company has created a technology platform that combines natural compounds with pharmaceutical agents to activate sirtuin pathways, aiming to prevent and treat chronic conditions associated with aging. Its flagship product, NS-0100, combines the natural compound leucine with a low dose of metformin to address type 2 diabetes, particularly for patients who experience gastrointestinal side effects from standard metformin treatment. NuSirt is currently conducting Phase 2 clinical trials to determine the optimal dosage of NS-0100. The company has filed eleven patent applications related to its technologies, with two patents already issued, and has successfully completed four clinical studies alongside various pre-clinical investigations.

Spyryx Biosciences, Inc. is a biopharmaceutical company specializing in the development of inhaled peptide therapeutics aimed at treating obstructive lung diseases, particularly cystic fibrosis (CF) and chronic obstructive pulmonary disease (COPD). Founded in 2013 by Dr. Robert Tarran, the company is headquartered in Durham, North Carolina. Spyryx's innovative approach is based on a novel mechanism discovered by Dr. Tarran, which regulates fluid on the lung's surface, a process that is disrupted in CF due to genetic mutations. This disruption leads to severe complications, including mucus accumulation and lung function decline. The company's therapeutic product has shown significant promise in preclinical studies by enhancing survival in animal models of CF, potentially offering a disease-modifying treatment for all CF patients, irrespective of their specific genetic mutations. Additionally, Spyryx is exploring the application of its technology for patients with COPD, who also experience issues related to lung dehydration and related complications.

Contego Medical, Inc. is a medical device company specializing in the development of embolic protection devices aimed at enhancing safety and efficacy during cardiovascular and endovascular procedures. Founded in 2005 and headquartered in Raleigh, North Carolina, with an additional office in Curitiba, Brazil, the company offers a range of integrated products, including angioplasty balloons and stent delivery catheters designed for interventions in carotid artery disease, peripheral artery disease, and deep vein thrombosis. Notably, Contego Medical has received FDA clearance for several innovative devices, such as the Paladin Carotid PTA Balloon System, the Vanguard IEP Peripheral Balloon Angioplasty System, and the Excipio SV Thrombectomy Device. Its technology integrates embolic protection directly onto the treatment catheter, streamlining procedures and improving patient outcomes.

PhaseBio Pharmaceuticals, Inc., established in 2002 and based in Malvern, Pennsylvania, is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for cardiopulmonary diseases. Its primary focus is on PB2452, a reversal agent for the antiplatelet drug ticagrelor, currently in Phase III trials for managing uncontrolled bleeding events or urgent surgeries. Additionally, PhaseBio is developing PB1046, a fusion protein in Phase IIb trials for treating pulmonary arterial hypertension, and PB6440, an oral agent for resistant hypertension. The company's proprietary technology, elastin-like polypeptides (ELPs), enhances the stability, bioavailability, and efficacy of proteins and peptides, aiming to improve patient outcomes and reduce side effects.

Graybug Vision, Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative treatments for diseases affecting the retina and optic nerve. Founded in 2011 and based in Redwood City, California, the company focuses on chronic vision-threatening conditions. Its lead product candidate, GB-102, is an intravitreal injection undergoing clinical trials for wet age-related macular degeneration and diabetic macular edema. Additionally, Graybug is advancing GB-103, a once-a-year formulation aimed at treating diabetic retinopathy, and GB-401, a depot formulation targeting primary open-angle glaucoma. The company utilizes proprietary micro- and nanoparticle controlled release technologies to enhance drug delivery in ocular tissues, thereby improving patient compliance and clinical outcomes. Graybug Vision was previously known as Graybug LLC before its rebranding in 2016.

ORIG3N, Inc. is a biotechnology company focused on developing innovative treatments for rare genetically inherited diseases, particularly targeting conditions related to the heart, liver, and neurodegeneration. Founded in 2014 and based in Boston, Massachusetts, ORIG3N utilizes induced pluripotent stem cell technology that allows for the differentiation of cells into any type found in the body. This technology is employed to test drug efficacy, screen for medication toxicity, and create personalized treatment pathways. The company offers a range of products, including LifeProfiles, which provides genetic insights related to fitness, metabolism, and exercise recovery; the Run DNA test for optimizing running performance; AURA, which assesses skin health; and Life Capsule, a repository for blood cells aimed at regenerative medicine development.

G1 Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Research Triangle Park, North Carolina, focused on the discovery, development, and commercialization of small molecule therapeutics for cancer treatment. The company is advancing several key drug candidates, including trilaciclib, an intravenous cyclin-dependent kinases (CDK) 4/6 inhibitor currently in Phase 1b/2 clinical trials for extensive-stage small cell lung cancer and Phase 2 trials for first-line small cell lung cancer and metastatic triple-negative breast cancer. Additionally, G1 is developing lerociclib, an oral CDK4/6 inhibitor in Phase 1b/2a trials for breast cancer and Phase 1b trials for non-small cell lung cancer, as well as rintodestrant, an oral selective estrogen receptor degrader in Phase I/2 trials. The company collaborates with Quantum Leap Healthcare Collaborative to explore trilaciclib's potential in neoadjuvant treatment for locally advanced breast cancer. Founded in 2008, G1 Therapeutics aims to address unmet medical needs in oncology by enhancing the effectiveness of existing cancer therapies.

Lysosomal Therapeutics, Inc. is a biotechnology company focused on discovering and developing small-molecule therapies for severe neurological diseases. Founded in 2011 and based in Cambridge, Massachusetts, the company targets disorders such as Gaucher-related neurodegeneration, Parkinson’s disease, and other synucleinopathies. Lysosomal Therapeutics employs a unique molecular platform informed by the clinically validated connection between lysosomal disorders and neurodegeneration. This approach facilitates the development of innovative treatment options aimed at improving the health and quality of life for patients affected by these debilitating conditions.

Clinipace Inc. is a clinical research organization based in Morrisville, North Carolina, with additional offices in Boulder, Colorado, Buenos Aires, Argentina, São Paulo, Brazil, and various locations in Europe and Asia Pacific. Founded in 2003, the company provides fully integrated clinical research services tailored for venture-backed, mid-tier, and strategic pharmaceutical, biotechnology, and medical device companies both in the United States and internationally. Clinipace specializes in a range of therapeutic areas, including oncology, nephrology, gastroenterology, cardiology, and immunology, among others. Its comprehensive suite of services encompasses project management, clinical monitoring, biostatistics, patient recruitment, regulatory affairs, and legal representation, allowing for a collaborative and flexible approach to clinical research that distinguishes it from traditional contract research organizations.

Viamet Pharmaceuticals is a biopharmaceutical company specializing in the discovery and development of innovative therapies that target metalloenzymes, employing its proprietary Metallophile Technology. This technology leverages expertise in bioinorganic chemistry to identify and optimize small molecule compounds that inhibit validated metalloenzymes, which are crucial for various therapeutic applications. Viamet focuses on creating best-in-class treatments for serious conditions, including invasive fungal infections, cancer, cardiovascular diseases, and orphan diseases, by enhancing the therapeutic potential of existing metalloenzyme inhibitors. Through its unique approach, Viamet aims to deliver novel, patentable therapeutic agents that effectively disrupt the cellular utilization of essential metal ions such as zinc and iron.

Clearside Biomedical, Inc. is a biopharmaceutical company focused on developing treatments for serious eye diseases with the aim of restoring and preserving vision. Founded in 2011 and headquartered in Alpharetta, Georgia, the company specializes in a proprietary ocular microinjection platform that allows for targeted delivery of therapeutic products to specific compartments of the eye. This innovative approach includes the use of the SCS Microinjector for administering therapies directly into the suprachoroidal space, enabling a non-surgical, repeatable procedure. Among its product pipeline, Clearside is developing XIPERE, a triamcinolone acetonide injectable suspension for macular edema, and CLS-AX, an axitinib for suprachoroidal injection. The company is dedicated to advancing pharmacological therapies for sight-threatening conditions by ensuring precise and effective treatment delivery.

Clinverse is a technology company that specializes in the financial management of clinical trials and related payments across more than 140 currencies. Its primary offering, ClinPay, is an online eClinical Trial Payment Network designed to enhance the efficiency of the investigator payment process. By connecting sponsors directly with investigators, ClinPay streamlines payment and reporting, leading to reduced study start-up times and improved accuracy in payments. The platform also provides essential features such as transparency, comprehensive auditing records, and simplified compliance, all of which contribute to increased productivity in clinical trials.

Lysosomal Therapeutics, Inc. is a biotechnology company focused on discovering and developing small-molecule therapies for severe neurological diseases. Founded in 2011 and based in Cambridge, Massachusetts, the company targets disorders such as Gaucher-related neurodegeneration, Parkinson’s disease, and other synucleinopathies. Lysosomal Therapeutics employs a unique molecular platform informed by the clinically validated connection between lysosomal disorders and neurodegeneration. This approach facilitates the development of innovative treatment options aimed at improving the health and quality of life for patients affected by these debilitating conditions.

Jumo Health is a New York-based company founded in 2009 that specializes in developing age-appropriate and culturally sensitive educational resources for patients and caregivers. The company collaborates with healthcare providers, manufacturers, and advocacy groups to deliver these resources at critical points in the medical journey, including diagnosis, treatment, and clinical trials. Jumo Health focuses on simplifying complex medical topics through engaging mediums such as comic books, animation, virtual reality experiences, and documentary-style patient stories. By employing visual elements and familiar formats, Jumo Health aims to enhance understanding and accessibility of evidence-based medical literature for diverse audiences.

Curoverse, Inc. is a Boston-based company that develops and operates a cloud-based open-source platform named Arvados, which focuses on the storage, organization, analysis, and sharing of genomic and biomedical data. Originally incorporated in 2010 as Clinical Future, Inc., the company rebranded in December 2013. Curoverse employs open-source software to provide management and computational services tailored to the unique needs of genomic data, empowering scientists and clinicians to facilitate breakthrough discoveries and enhance patient care. The Arvados platform allows for secure access to patient-level genomic and health data, supporting drug development and precision medicine by enabling the management, processing, analysis, and sharing of extensive biomedical data sets, including genomics and imaging.

Sideris Pharmaceuticals Inc. is a privately held biopharmaceutical company that is focused on development of therapeutics for the treatment of transfusion-related iron overload. The company’s operations include facilities in Boston, MA, and in Gainesville, FL.

G1 Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Research Triangle Park, North Carolina, focused on the discovery, development, and commercialization of small molecule therapeutics for cancer treatment. The company is advancing several key drug candidates, including trilaciclib, an intravenous cyclin-dependent kinases (CDK) 4/6 inhibitor currently in Phase 1b/2 clinical trials for extensive-stage small cell lung cancer and Phase 2 trials for first-line small cell lung cancer and metastatic triple-negative breast cancer. Additionally, G1 is developing lerociclib, an oral CDK4/6 inhibitor in Phase 1b/2a trials for breast cancer and Phase 1b trials for non-small cell lung cancer, as well as rintodestrant, an oral selective estrogen receptor degrader in Phase I/2 trials. The company collaborates with Quantum Leap Healthcare Collaborative to explore trilaciclib's potential in neoadjuvant treatment for locally advanced breast cancer. Founded in 2008, G1 Therapeutics aims to address unmet medical needs in oncology by enhancing the effectiveness of existing cancer therapies.

Clearside Biomedical, Inc. is a biopharmaceutical company focused on developing treatments for serious eye diseases with the aim of restoring and preserving vision. Founded in 2011 and headquartered in Alpharetta, Georgia, the company specializes in a proprietary ocular microinjection platform that allows for targeted delivery of therapeutic products to specific compartments of the eye. This innovative approach includes the use of the SCS Microinjector for administering therapies directly into the suprachoroidal space, enabling a non-surgical, repeatable procedure. Among its product pipeline, Clearside is developing XIPERE, a triamcinolone acetonide injectable suspension for macular edema, and CLS-AX, an axitinib for suprachoroidal injection. The company is dedicated to advancing pharmacological therapies for sight-threatening conditions by ensuring precise and effective treatment delivery.